Introduction
Plasminogen activator inhibitor-1 (PAI-1) is an important inhibitor of fibrinolytic systems [1] . It reacts with single and two-chain t-PA and with two-chain u-PA inhibiting target proteinases by formation of a 1 : 1 stoichiometric reversible complex; the rapid inhibition of both t-PA and u-PA involves a reversible high-affinity between three negatively charged amino acids of PAI-1 and highly positively charged regions in t-PA or in u-PA, binding to fibrin and inhibiting t-PA-mediated fibrin dissolution [2] . Increased levels of PAI-1 [3] were observed in carriers of PAI-1 promoter polymorphism (4G/5G or 4G/4G) of the PAI-1 gene, which is associated, especially in patients with 4G/4G polymorphism [4] with reduced fibrinolytic activity; several articles show that this polymorphism may be found in experimental models and in men with thrombotic disorders.
Recently, reduced fibrinolytic activity and increased levels of PAI-1 have been reported in men with several arterial thrombotic diseases [5] [6] [7] [8] [9] [10] [11] [12] , although there is conflicting evidence regarding the relationship between this polymorphism and the risk of venous thromboembolism, despite the results of experimental models [13] [14] [15] [16] [17] [18] .
Apart from many risk factors that may give rise to thrombosis were identified in patients with venous thromboembolism. The most common congenital risk factors are the G-A substitution at 1691 nucleotide of the factor V gene, which provokes the resistance of activated protein C and the G to A polymorphism at nucleotide 20210 in the 3 0 -untranslated region of the prothrombin gene; this might be associated with increased prothrombin activity in plasma.
In men, reduced fibrinolytic activity, due to increased plasma PAI-1 levels normally associated with the allele 4G, may well represent an additional risk factor in carriers of factor V Leiden or prothrombin G20210A mutation [19, 20] . We carried out a study comparing one group of patients who developed postsurgical calf vein thrombosis (with extension of thrombotic lesions to popliteal or femoral veins) with a group of patients who had developed postsurgical calf vein thrombosis (without extension of thrombotic lesions) in order to evaluate whether the presence of PAI-1 promoter polymorphism 4G/4G would significantly influence the proximal extension of vein thrombosis in spite of anticoagulant treatment.
In this study, we considered only the patients with CVT (total 226); in this group the CVT was diagnosed 12 AE 2.1 days after surgery, and all the patients were treated daily with nadroparin calcium anti-Xa [24] [25] [26] at a dosage of 90 IU/kg body weight, given in two administrations daily. At the same time, sodium warfarin was started, halting the administration of nadroparin until the International Normalized Ratio had stabilized between two and three. Heparin treatment was stopped in all patients after 5 or 6 days. The sodium warfarin treatment was prolonged for 12 weeks in all patients. The exclusion criteria were as follows: presence of cancer, malignant haematological diseases, hyperhomocystinemia, hyperviscosity syndromes or antiphospholipid antibodies, the presence of factor V Leiden, prothrombin 20210 G-A mutation, clinical history of previous episodes of deep-venous thrombosis or pulmonary embolism. The presence of cancer is shown by means of a tumoral marker dosage, whereas hyperhomocystenemia by the Medical Systems Immulite and Immulite 1000 analyzers DPC -Diagnostic Products Corporation USA. The Brookfield DW3 viscosimeter-USA for high and low shear rate, was used to exclude haemorheological disorders such as haematic hyperscosity; lastly, using the Elisa test kit that provides a quantitative in-vitro assay for human autoantibodies of the IgM or IgG class against cardiolipin in serum, we ruled out patients with antiphospholipid antibodies; The upper limit of the normal range (cut-off) is 12 Phospholipid-IgG or IgM-units/ml. The calibration of the controls is performed in PL-IgG-units using an international human standard serum (Louisville APL Diagnostics, USA). The presence of the Factor V Leiden and the G20210A mutation for the protrombin gene was excluded by means of the same method used for 4G/5G polymorphism.
Out of 226 patients with CVT, 168 were included and 58 were excluded because they met at least one of the exclusion criteria. These patients were followed up, an ultrasound examination by echo colour Doppler (ATL HDI 1500, Madison Co Ltd. Korea) being carried out once a week for 12 weeks to detect any extension of the thrombotic lesion. This test was carried out by the same physician on the same patient, in a room at 22-258C, with the patient in the clinostatic position and at a 458 angle.
For each vein examined a compression was performed by the probe, thus, registering the flow changes. In order to check thrombotic extension, the primary end-point showed there was no shutting out of the vein wall after compression, whereas the secondary end-points were flow velocity and colour distribution variations.
During the follow-up, patients were considered positive for thrombotic lesion extension when they presented thrombosis of the popliteal and/or femoral vein. The group of 168 patients with CVT was subdivided as follows:
(1) the group of patients with thrombosis progression in the popliteal or femoral vein numbered 50 (34 men and 16 women) aged between 54 and 62 years (mean age 58 AE 2 SD). The extension was diagnosed 14 AE 1.8 days after CVT detection. (2) the group of patients without thrombosis progression numbered 118 (78 men and 40 women) aged between 55 and 66 years (mean age 60 AE 2 SD) ( Table 1) .
We also enrolled 70 healthy controls (41 men and 29 women) aged between 57 and 65 years (mean age 60.314 AE 2.39 SD) chosen among medical and paramedical personnel and students of Palermo University, Medical School.
We analyzed the PAI-1 promoter polymorphism 4G/5G in all patients and in 70 healthy controls, using nuclear laser medicine methods [27, 28] , which included three steps:
(1) DNA isolation from fresh or frozen blood with ethylenediaminetetracetate or citrate anticoagulant. (2) PCR amplification using an amplification mix containing biotinylated primers added to Taq DNA polymerase (1U) and DNA template (25-200 ng). (3) Hybridization of amplification products with a test strip containing allele-specific oligonucleotide probes immobilized as an array of parallel lines. The test strips were inserted and incubated for 30 min at 458C in a water-bath with shaking platform and subsequently two stringent washes at 458C were performed. For colour development 1 ml of Conjugate Solution containing streptavidin-alkaline phosphatase was added to the strip test and incubated in an orbital shaker at room temperature for 15 min. Each strip was added to 1 ml of Colour Developer.
After an incubation period of 15 min at room temperature in the dark, the genotype of the sample was determined.
We also studied plasmatic PAI-1 activity in all patients and healthy controls using the Berichrom PAI methodDade Behring Inc. Newark, Delaware, USA.
The principle of this method is based on the deactivation of urokinase by PAI-1 contained in plasma. The remaining urokinase activity is determined by the conversion of plasminogen into plasmin. The resulting plasmin is measured by the segregation of a chromogen substrate at 405 nm (concentration through plasminogenolysis).
The destructive alfa2-antiplasmin is deactivated through oxidation with chloramine T. In healthy adults PAI-1 activity lay between 0.3 and 3.5 U/ml. The study was approved by the Ethics Committee of the University Hospital and informed consent was obtained from all participants in the study.
The statistical analysis was carried out using a SYSTAT DATA software package, version 5.2 (Systat, Evanston, Illinois, USA).
The presence of 4G/5G polymorphism was compared in two groups of patients, and healthy controls using the x 2 test with Yates correction. The results of the plasma activity of PAI-1 were expressed as mean and SD. The mean difference between the groups was evaluated using the Student's t-test for unpaired data. The null hypothesis was rejected for a value of P less than 0.05.
The probability of turning out carriers of 675 4G/5G polymorphism was calculated in CVT progression patients vs. CVT nonprogression patients, by odds ratio (OR) adjusted for sex and 95% confidence interval (CI) using logistic regression analysis.
Results and discussion
The results of 4G/5G and 4G/4G genotype frequency in the groups are illustrated in Table 2 .
The 4G/5G genotype was found in 12 patients from the first group and in 15 patients from the second group, and the 4G/4G genotype was only found in two patients from the first group. The 4G/5G genotype was also found in seven healthy controls and the 4G/4G genotype was only found in one healthy control.
Statistical analysis showed that the presence of the 4G/5G and 4G/4G genotype significantly increased in the group of patients with thrombosis progression when compared with the healthy controls. No significant differences were observed between the group of patients without thrombosis progression and the healthy controls. Statistical analysis also showed that the presence of 4G/5G and 4G/4G genotype significantly increased in the group with thrombosis progression when compared with the group of patients without thrombosis progression; this presence was also associated with an increase in CVT progression risk (OR adjusted for sex 2.692; 95% CI 1.302-4.702). The difference between the group of patients with thrombosis progression and the one without thrombosis progression was meaningful for 4G allele presence, but, because of the limited number of patients with the 4G/4G genotype, it will be necessary to wait for further evidence.
The mean results of plasma PAI-1 activity in the two groups are illustrated in Table 3 . The mean of PAI-1 activity was 3.2 U/l in the group with thrombosis progression, the SD being 0.27, 2.6 U/l in the group without thrombosis progression, the SD being 0.24, and 2.5 U/l in healthy controls, the SD being 0.35 U/l. Statistical analysis showed that the plasma activity of PAI-1 significantly increased in the first group of patients when compared with the second group of patients and to the healthy controls. No significant differences were observed between the second group and the healthy 4G/5G polymorphism and calf vein thrombosis Ferrara et al. 239 's t-test) .
MMM PAI-1 plasmatic activity in patients with extension-CVT vs. healthy controls: P ¼ 0.0001 (Student's t-test).
controls. There might be two explanations for the absence of statistical significance between the group of patients with CVT, but without progression, and the healthy controls: the first being that these patients had a thrombosis that was limited to one calf vein only, and, often, not completely occluded; the second being that the thrombotic lesions healed quickly and without complications.
Several studies have suggested that increased in-vivo levels of PAI-1 promote fibrin deposition. This deposition, associated with increased PAI-1 expression, was observed with the aging process and may contribute to the development of thrombosis [29] . In patients with 4G/5G polymorphism the presence of 4G allele reduced fibrinolytic activity because only 5G allele contains an additional binding site for a DNA-binding protein, which might be a transcriptional repressor for PAI-1 formation [30] .
In men, decreased fibrinolytic activity was reported in several thrombotic diseases, including arterial and venous thrombosis [31] [32] [33] . Decreased fibrinolytic activity was related to an increased level of PAI activity and to the presence of the 4G allele in young patients with myocardial infarction [34, 35] ; this polymorphism was considered a risk factor, but this data has not been confirmed in other studies [36] .
Sartori et al. [37] and Stegnar et al. [38] demonstrated a PAI-1-induced hypofibrinolysis related to the presence of the 4G allele among deep-vein thrombosis patients. To date, there are no studies demonstrating the connection between DVT onset, 4G/5G polymorphism and the fibrinolytic activity decrease, in patients with increased levels of PAI-1.
Moreover, the role of 4G/5G polymorphism in the pathogenesis of DVT is not universally recognized. We hypothesize that the persistence of thrombosis and its progression may be partially associated with the 4G/5G polymorphism and the decreased fibrinolytic activity. Our results showed a higher overall incidence of thrombosis progression than other studies in which patients were not assessed by genetic profile.
The incidence of thrombotic progression was found in patients with calf vein thrombosis in percentages ranging between 4 and 15% [39] [40] [41] [42] [43] ; our percentage was overall 27.70%. Because we excluded from this study patients with the presence of factor V Leiden and/or G20210A prothrombin mutation genes, we believe that the extension of thrombosis could be related to the increase in the PAI 1 activity, which reduces fibrinolytic activity. However, in a recent article, Sibbing et al. [44] showed that the PAI-1 4G/5G polymorphism has no impact on the amount of myocardial salvage achieved by reperfusion with stenting or thrombolysis, in patients with AMI. For this reason polymorphism 4G/5G may have a minor role in rethrombosis. We found a relation between the progression of thrombosis and the presence of 4G/5G polymorphism in venous diseases. We believe that, as the blood-flow velocity in arteries [45, 46] is greater than in veins [47, 48] this could explain the different data. Moreover, in the presence of thrombosis vein occlusion this velocity is lowest near the thrombus. We believe that this very low velocity might favour the progression of thrombotic lesions, especially in patients with 4G/5G polymorphism, because of reduced fibrinolytic activity and reduced lysis of clots.
However, our data cannot be considered exhaustive because of the limited number of cases involved; but, if these results are confirmed by further studies, they may prove useful for the management and treatment of venous thromboembolism in carriers of 4G allele.
The treatment of patients with CVT is still controversial [49] , even though the results of the Duré e Optimale du Traitement AntiVitamines K (DOTAVK) study [50] recommend treatment with oral anticoagulants (limited to a few weeks), whereas other studies invariably recommend the use of the low-molecular-weight heparin for a very limited period. We have preferred to follow the DOTAVK study, which envisages the use of the oral anticoagulant, even though such therapy may well prove inadequate in preventing the progression of thrombosis in carriers of allele 4G. Association with sulodexide [51, 52] , mesoglicano [53] or defibrotide [54, 55] might well limit the process of extension of the thromboses because of their effect on the fibrinolysis. However, this needs to be demonstrated, and at the moment represents a hypothesis which needs working on.
